ELMS STEVE
Insider CIK 1250195 · PTX Director · SNSS 10% owner · MRKR Director · AMBI Director · AGRX Director, 10% owner · ADMA Director, 10% owner · ZLTQ 10% owner · ESPR 10% owner · CEMP 10% owner · TTOO Director, 10% owner · VSAR 10% owner · DRTX 10% owner · SYRS 10% owner · LOXO Director, 10% owner · ZSAN Director, 10% owner · CDTX Director · ELEV Director, 10% owner · SFES.OB 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ADMA ADMA BIOLOGICS, INC. | P Buy | 2026-03-06 | 2026-03-09 | 7,000 | $15.39 | $107.7K | 2,045,730 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | P Buy | 2026-03-05 | 2026-03-09 | 7,000 | $15.67 | $109.7K | 2,038,730 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2026-02-09 | 2026-02-11 | 17,730 | — | $0 | 17,730 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2026-02-09 | 2026-02-11 | 10,690 | — | $0 | 98,020 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2025-11-17 | 2025-11-19 | 137,330 | — | $0 | 137,330 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2025-11-17 | 2025-11-19 | 84,411 | — | $0 | 84,411 | SEC↗ |
| ELEV Elevation Oncology, Inc. | D To issuer deriv | 2025-07-23 | 2025-07-24 | 31,238 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | D To issuer deriv | 2025-07-23 | 2025-07-24 | 15,619 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | D To issuer deriv | 2025-07-23 | 2025-07-24 | 31,238 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | D To issuer deriv | 2025-07-23 | 2025-07-24 | 35,000 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | D To issuer deriv | 2025-07-23 | 2025-07-24 | 35,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2025-06-16 | 2025-06-16 | 194,749 | $20.24 | $3.94M | 87,330 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 53,172 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 55,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 30,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 17,500 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 53,837 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 10,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 9,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 37,541 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 51,630 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2025-06-13 | 2025-06-16 | 15,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 30,000 | $3.89 | $116.7K | 207,667 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 15,000 | $2.92 | $43.8K | 222,667 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 55,000 | $2.35 | $129.3K | 277,667 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 53,172 | $1.67 | $88.8K | 330,839 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 51,630 | $3.35 | $173.0K | 382,469 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 10,000 | $5.00 | $50.0K | 106,330 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 9,000 | $5.96 | $53.6K | 96,330 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 17,500 | $4.91 | $85.9K | 177,667 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 53,837 | $3.66 | $197.0K | 160,167 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2025-06-13 | 2025-06-16 | 137,931 | $20.82 | $2.87M | 282,079 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2025-06-13 | 2025-06-16 | 37,541 | $5.40 | $202.7K | 420,010 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2025-06-12 | 2025-06-16 | 92,941 | $21.69 | $2.02M | 2,031,730 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 35,000 | — | $0 | 35,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2025-02-19 | 2025-02-21 | 16,279 | — | $0 | 16,279 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2025-02-19 | 2025-02-21 | 10,889 | — | $0 | 87,330 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2025-02-12 | 2025-02-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | P Buy | 2024-12-23 | 2024-12-26 | 11,085 | $3.20 | $35.5K | 325,370 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise deriv | 2024-11-27 | 2024-12-02 | 9,000 | — | $0 | 0 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | M Exercise | 2024-11-27 | 2024-12-02 | 9,000 | $10.80 | $97.2K | 2,124,671 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2024-06-13 | 2024-06-17 | 35,000 | — | $0 | 35,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2024-03-19 | 2024-03-19 | 411,829 | $6.08 | $2.50M | 2,115,671 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2024-03-18 | 2024-03-19 | 49,887 | $6.01 | $299.8K | 2,527,500 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2024-03-15 | 2024-03-15 | 183,008 | $6.01 | $1.10M | 2,577,387 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2024-03-14 | 2024-03-15 | 448,276 | $6.05 | $2.71M | 2,760,395 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | S Sale | 2024-03-13 | 2024-03-15 | 407,000 | $6.21 | $2.53M | 3,208,671 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2024-02-26 | 2024-02-28 | 37,541 | — | $0 | 37,541 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2024-02-26 | 2024-02-28 | 24,040 | — | $0 | 76,441 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2023-06-16 | 2023-06-21 | 31,238 | — | $0 | 31,238 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2023-06-06 | 2023-06-08 | 8,000 | — | $0 | 8,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2023-03-06 | 2023-03-08 | 51,630 | — | $0 | 51,630 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2023-03-06 | 2023-03-08 | 25,815 | — | $0 | 52,401 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2022-06-17 | 2022-06-22 | 15,619 | — | $0 | 15,619 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2022-05-24 | 2022-05-26 | 80,000 | — | $0 | 80,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2022-03-07 | 2022-03-09 | 53,172 | — | $0 | 53,172 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2022-03-07 | 2022-03-09 | 26,586 | — | $0 | 26,586 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion deriv | 2021-06-29 | 2021-07-01 | 8,000,000 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion deriv | 2021-06-29 | 2021-07-01 | 1,936,834 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | P Buy | 2021-06-29 | 2021-07-01 | 187,500 | $16.00 | $3.00M | 2,834,910 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion | 2021-06-29 | 2021-07-01 | 458,360 | — | $0 | 2,647,410 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion | 2021-06-29 | 2021-07-01 | 1,893,232 | — | $0 | 2,189,050 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2021-06-24 | 2021-06-28 | 31,238 | — | $0 | 31,238 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award deriv | 2021-06-10 | 2021-06-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2021-06-10 | 2021-06-14 | 15,000 | — | $0 | 22,500 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award | 2021-06-08 | 2021-06-10 | 12,658 | — | $0 | 29,680 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | P Buy | 2021-03-16 | 2021-03-18 | 1,142,857 | $1.75 | $2.00M | 3,142,857 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2021-02-25 | 2021-03-01 | 55,000 | — | $0 | 55,000 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2020-06-25 | 2020-06-29 | 7,500 | — | $0 | 7,500 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award deriv | 2020-06-03 | 2020-06-05 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2020-02-28 | 2020-05-01 | 7,500 | — | $0 | 7,500 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2020-02-28 | 2020-03-03 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award | 2020-02-28 | 2020-03-03 | 7,500 | — | $0 | 7,500 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2019-12-02 | 2019-12-06 | 689,655 | $1.45 | $1000.0K | 2,718,226 | SEC↗ |
| MRKR Marker Therapeutics, Inc. | A Award deriv | 2019-08-06 | 2019-08-08 | 12,500 | — | $0 | 12,500 | SEC↗ |
| SNSS SUNESIS PHARMACEUTICALS IN | P Buy | 2019-07-15 | 2019-07-15 | 2,500,000 | $0.60 | $1.50M | 10,100,000 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2019-04-11 | 2019-04-12 | 428,571 | $3.50 | $1.50M | 2,028,571 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2019-03-13 | 2019-03-15 | 30,000 | — | $0 | 30,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | D To issuer deriv | 2019-02-15 | 2019-02-15 | 11,000 | $235.00 | $2.58M | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | D To issuer deriv | 2019-02-15 | 2019-02-15 | 8,750 | $235.00 | $2.06M | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | D To issuer deriv | 2019-02-15 | 2019-02-15 | 15,625 | $235.00 | $3.67M | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | D To issuer deriv | 2019-02-15 | 2019-02-15 | 7,812 | $235.00 | $1.84M | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | D To issuer deriv | 2019-02-15 | 2019-02-15 | 7,812 | $235.00 | $1.84M | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | U Tender | 2019-02-15 | 2019-02-15 | 2,038,920 | $235.00 | $479.15M | 2,038,920 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award deriv | 2019-01-02 | 2019-07-18 | 1,500 | — | $0 | 1,500 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2018-07-10 | 2018-07-12 | 1,400,000 | $179.43 | $251.20M | 2,038,920 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2018-06-22 | 2018-06-25 | 17,500 | — | $0 | 17,500 | SEC↗ |
| LOXO Loxo Oncology, Inc. | A Award deriv | 2018-06-13 | 2018-06-14 | 8,750 | — | $0 | 8,750 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award deriv | 2018-05-17 | 2018-05-21 | 25,000 | — | $0 | 25,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-12-19 | 2017-12-20 | 250,000 | $80.50 | $20.13M | 3,438,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-11-22 | 2017-11-27 | 500,000 | $75.00 | $37.50M | 3,688,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | A Award deriv | 2017-06-22 | 2017-06-23 | 11,000 | — | $0 | 11,000 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2017-06-06 | 2017-06-08 | 53,837 | — | $0 | 53,837 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2017-02-14 | 2017-02-16 | 10,000 | — | $0 | 10,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2017-01-10 | 2017-01-12 | 160,000 | $31.00 | $4.96M | 4,188,920 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion deriv | 2016-07-06 | 2016-07-06 | 1,907,122 | — | $0 | 0 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion | 2016-07-06 | 2016-07-06 | 508,565 | — | $0 | 508,565 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2016-07-06 | 2016-07-06 | 400,000 | $12.50 | $5.00M | 908,565 | SEC↗ |
| LOXO Loxo Oncology, Inc. | A Award deriv | 2016-06-10 | 2016-06-13 | 7,812 | — | $0 | 7,812 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | J Other | 2016-06-02 | 2016-06-03 | 400,000 | — | $0 | 2,583,797 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | P Buy deriv | 2016-05-26 | 2016-05-31 | 40,000 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2016-05-17 | 2016-05-19 | 232,558 | $21.50 | $5.00M | 4,028,920 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2016-01-28 | 2016-02-01 | 9,000 | — | $0 | 9,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-12-11 | 2015-12-15 | 200 | $27.50 | $5.5K | 3,796,362 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2015-12-09 | 2015-12-09 | 307,692 | $9.75 | $3.00M | 2,830,992 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-17 | 2015-11-19 | 265,000 | $26.50 | $7.02M | 3,796,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-13 | 2015-11-16 | 1,955 | $27.47 | $53.7K | 3,531,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-12 | 2015-11-16 | 76,714 | $27.65 | $2.12M | 3,529,207 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | P Buy deriv | 2015-08-14 | 2015-08-18 | 40,000 | — | $0 | 40,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | A Award deriv | 2015-07-28 | 2015-07-30 | 7,812 | — | $0 | 7,812 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-24 | 2015-04-27 | 5,743 | $108.00 | $620.2K | 1,898,851 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-24 | 2015-04-27 | 61,726 | $106.10 | $6.55M | 1,837,125 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-23 | 2015-04-27 | 150,000 | $109.10 | $16.36M | 1,904,594 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | P Buy deriv | 2015-04-22 | 2015-04-24 | 2,500,000 | — | $0 | 2,500,000 | SEC↗ |
| CDTX Cidara Therapeutics, Inc. | C Conversion deriv | 2015-04-20 | 2015-04-22 | 8,928,572 | — | $0 | 0 | SEC↗ |
| CDTX Cidara Therapeutics, Inc. | C Conversion | 2015-04-20 | 2015-04-22 | 351,518 | — | $0 | 351,518 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2015-01-30 | 2015-02-03 | 9,000 | — | $0 | 9,000 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2015-01-27 | 2015-01-29 | 145,000 | $17.25 | $2.50M | 2,139,568 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | P Buy | 2015-01-23 | 2015-01-27 | 811,966 | $5.85 | $4.75M | 2,983,797 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | X Exercise deriv | 2014-09-02 | 2014-09-04 | 2,362 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | X Exercise | 2014-09-02 | 2014-09-04 | 2,362 | $6.66 | $15.7K | 2,362 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 2,967,033 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 549,851 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion | 2014-08-12 | 2014-08-14 | 2,068,755 | — | $0 | 2,068,755 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2014-08-12 | 2014-08-14 | 454,545 | $11.00 | $5.00M | 2,523,300 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 506,960 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 2,343,749 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 506,960 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 2,343,749 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion | 2014-08-06 | 2014-08-06 | 2,850,709 | — | $0 | 3,039,416 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2014-08-06 | 2014-08-06 | 413,077 | $13.00 | $5.37M | 3,452,493 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion | 2014-08-06 | 2014-08-06 | 2,850,709 | — | $0 | 3,039,416 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2014-08-06 | 2014-08-06 | 413,077 | $13.00 | $5.37M | 3,452,493 | SEC↗ |
| LOXO Loxo Oncology, Inc. | A Award deriv | 2014-07-31 | 2014-08-01 | 15,625 | — | $0 | 15,625 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | A Award deriv | 2014-06-19 | 2014-06-23 | 9,000 | — | $0 | 9,000 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | P Buy deriv | 2014-06-18 | 2014-06-20 | 40,000 | — | $0 | 40,000 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 3,528 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 745,730 | — | $0 | 2,280,175 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | A Award deriv | 2014-05-15 | 2014-05-16 | 8,000 | — | $0 | 8,000 | SEC↗ |
| TRXC TRANSENTERIX INC. | P Buy | 2014-04-21 | 2014-04-23 | 1,037,767 | $4.00 | $4.15M | 8,335,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 14,222,222 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 403,704 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 1,479,993 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 654,796 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 5,486,820 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 1,236,715 | — | $0 | 1,271,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 35,104 | — | $0 | 35,104 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2014-03-26 | 2014-03-27 | 60,000 | $21.00 | $1.26M | 1,994,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 477,115 | — | $0 | 1,934,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 56,939 | — | $0 | 1,457,453 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 128,695 | — | $0 | 1,400,514 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-21 | 2014-03-21 | 2,649 | $15.57 | $41.2K | 3,030,175 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-20 | 2014-03-21 | 98,000 | $15.74 | $1.54M | 3,032,824 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,715 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 994,305 | — | $0 | 2,597,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,697 | — | $0 | 4,697 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 2,398 | — | $0 | 2,398 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 1,152 | — | $0 | 1,152 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion | 2013-12-06 | 2013-12-10 | 12,401,764 | — | $0 | 36,490,260 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2013-11-14 | 2013-11-15 | 575,000 | $12.22 | $7.03M | 3,597,742 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | P Buy | 2013-10-22 | 2013-10-23 | 411,765 | $8.50 | $3.50M | 3,620,143 | SEC↗ |
| SFES.OB SafeStitch Medical, Inc. | P Buy deriv | 2013-09-03 | 2013-09-05 | 1,240,176 | $4.00 | $4.96M | 1,240,176 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | J Other deriv | 2013-07-01 | 2013-07-01 | 497,666 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | C Conversion deriv | 2013-07-01 | 2013-07-01 | 1,816,475 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | J Other deriv | 2013-07-01 | 2013-07-01 | 71,237 | — | $0 | 71,237 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | P Buy | 2013-07-01 | 2013-07-01 | 238,119 | $14.00 | $3.33M | 2,054,594 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | C Conversion | 2013-07-01 | 2013-07-01 | 1,816,475 | — | $0 | 1,816,475 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | X Exercise deriv | 2013-05-22 | 2013-05-23 | 103,712 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | X Exercise | 2013-05-22 | 2013-05-23 | 103,712 | $0.02 | $2.1K | 1,650,156 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion deriv | 2013-05-21 | 2013-05-21 | 2,474,300 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion deriv | 2013-05-21 | 2013-05-21 | 10,953,433 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion deriv | 2013-05-21 | 2013-05-21 | 8,449,121 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | A Award deriv | 2013-05-21 | 2013-05-21 | 7,085 | — | $0 | 7,085 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion deriv | 2013-05-21 | 2013-05-21 | 1,378,747 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion deriv | 2013-05-21 | 2013-05-21 | 693,641 | — | $0 | 0 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion | 2013-05-21 | 2013-05-21 | 456,393 | — | $0 | 770,762 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion | 2013-05-21 | 2013-05-21 | 227,801 | — | $0 | 314,369 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | P Buy | 2013-05-21 | 2013-05-21 | 423,635 | $8.00 | $3.39M | 1,546,444 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion | 2013-05-21 | 2013-05-21 | 28,901 | — | $0 | 29,120 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion | 2013-05-21 | 2013-05-21 | 352,047 | — | $0 | 1,122,809 | SEC↗ |
| AMBI AMBIT BIOSCIENCES CORP | C Conversion | 2013-05-21 | 2013-05-21 | 57,448 | — | $0 | 86,568 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion deriv | 2012-07-24 | 2013-12-10 | 1,240,176 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion deriv | 2012-07-24 | 2012-07-25 | 16,157,707 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | P Buy | 2012-07-24 | 2012-07-25 | 1,111,111 | $9.00 | $10.00M | 3,130,824 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion | 2012-07-24 | 2012-07-25 | 2,019,713 | — | $0 | 2,019,713 | SEC↗ |
| NONE ADMA BIOLOGICS, INC. | A Award deriv | 2012-04-04 | 2012-04-05 | 13,258 | — | $0 | 13,258 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | A Award deriv | 2012-03-22 | 2012-04-18 | 10,000 | — | $0 | 10,000 | SEC↗ |
| PTX PERNIX THERAPEUTICS HOLDIN | A Award | 2012-03-22 | 2012-04-18 | 10,000 | — | $0 | 10,000 | SEC↗ |
| NONE R&R ACQUISITION VI, INC | A Award | 2012-02-13 | 2012-02-15 | 2,516,855 | — | $0 | 2,516,855 | SEC↗ |
| CEMP CEMPRA, INC. | P Buy | 2012-02-07 | 2012-02-09 | 1,213,663 | $6.00 | $7.28M | 3,293,060 | SEC↗ |